Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Akebia Therapeutics (AKBA) Gross Profit (2018 - 2026)

Akebia Therapeutics has reported Gross Profit over the past 7 years, most recently at $45.1 million for Q4 2025.

  • Quarterly Gross Profit fell 27.48% to $45.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $196.7 million through Dec 2025, up 30.23% year-over-year, with the annual reading at $196.7 million for FY2025, 47.87% up from the prior year.
  • Gross Profit was $45.1 million for Q4 2025 at Akebia Therapeutics, down from $49.4 million in the prior quarter.
  • Over five years, Gross Profit peaked at $116.8 million in Q2 2022 and troughed at -$163.7 million in Q4 2021.
  • The 5-year median for Gross Profit is $32.5 million (2021), against an average of $29.8 million.
  • Year-over-year, Gross Profit tumbled 471.63% in 2021 and then surged 27836.84% in 2022.
  • A 5-year view of Gross Profit shows it stood at -$163.7 million in 2021, then soared by 119.66% to $32.2 million in 2022, then surged by 128.64% to $73.6 million in 2023, then decreased by 15.49% to $62.2 million in 2024, then fell by 27.48% to $45.1 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Gross Profit are $45.1 million (Q4 2025), $49.4 million (Q3 2025), and $52.6 million (Q2 2025).